Business Standard

USFDA audit finds no flaws in Cadila Healthcare Moraiya unit

Plant has received several product approvals after audit. eyes 40 in all in FY18

File photo of Cadila Healthcare's Moraiya facility
Premium

File photo of Cadila Healthcare's Moraiya facility

BS Reporter Ahmedabad
Ahmedabad-based Cadila Healthcare (Zydus Cadila) on Wednesday said its formulations manufacturing facility at Moraiya, near Ahmedabad, has received an Establishment Inspection Report (EIR) from the US Food and Drugs Administration signifying the successful closure of the audit. 

The Moraiya manufacturing plant had completed the USFDA audit from February 6 to 15 earlier this year, with zero adverse observations. 

Post the audit, the plant has received several product approvals, including the final approval to market Mesalamine delayed-release tablets in the US. Earlier this month, it received USFDA approval for an antibacterial injection from Levofloxacin for its Moraiya plant. 

As such with

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in